NASDAQ:RGEN - Repligen Stock Price, Forecast & News

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen Co. (NASDAQ:RGEN) released its earnings results on Thursday, October, 31st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.07. The biotechnology company earned $69.45 million during the quarter, compared to analyst estimates of $66.10 million. Repligen had a net margin of 9.28% and a return on equity of 6.50%. The firm's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 EPS. View Repligen's Earnings History.

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Repligen.

Repligen issued an update on its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $1.00-1.04 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.97. The company issued revenue guidance of $267-270 million, compared to the consensus revenue estimate of $266.06 million.

7 brokerages have issued 12-month price objectives for Repligen's stock. Their forecasts range from $100.00 to $110.00. On average, they expect Repligen's share price to reach $106.14 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price. View Analyst Price Targets for Repligen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.

News headlines about RGEN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Repligen earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Repligen.

Repligen saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 2,420,000 shares, a drop of 29.4% from the December 31st total of 3,430,000 shares. Based on an average trading volume of 393,500 shares, the short-interest ratio is presently 6.1 days. Approximately 5.1% of the company's stock are sold short. View Repligen's Current Options Chain.

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Xilinx (XLNX), salesforce.com (CRM), Corcept Therapeutics (CORT), Micron Technology (MU), Fortinet (FTNT) and Okta (OKTA).

Repligen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (2.43%), California Public Employees Retirement System (0.36%), Summit Creek Advisors LLC (0.16%), New York State Teachers Retirement System (0.08%), Arizona State Retirement System (0.05%) and Virginia Retirement Systems ET AL (0.04%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

RGEN stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Eqis Capital Management Inc., Arizona State Retirement System, Virginia Retirement Systems ET AL, State of Alaska Department of Revenue, Summit Creek Advisors LLC, Strs Ohio and Sheets Smith Wealth Management. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes and Ralf Kuriyel. View Insider Buying and Selling for Repligen.

RGEN stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Assenagon Asset Management S.A., NewSquare Capital LLC, Dupont Capital Management Corp, Janney Montgomery Scott LLC, Ballentine Partners LLC, Allred Capital Management LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Repligen.

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGEN stock can currently be purchased for approximately $99.62.

Repligen has a market capitalization of $5.19 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen.

The official website for Repligen is http://www.repligen.com/.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]